Envafolimab and Chidamide in combination with GEMOX as first-line treatment for advanced and metastatic biliary tract cancer: A single-arm, exploratory, phase 2 trial
Latest Information Update: 13 Jan 2025
Price :
$35 *
At a glance
- Drugs Envafolimab (Primary) ; Tucidinostat (Primary) ; Gemcitabine; Oxaliplatin
- Indications Biliary cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms B-Enefits
- 13 Jan 2025 New trial record